Xeris Biopharma Balance Sheet
NASDAQ: XERSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xeris Biopharma financial position
At the end of fiscal 2025, Xeris Biopharma reported total assets of $383.5 million, up 18.7% from a year earlier against total liabilities of $369.8 million. Shareholders' equity stood at $13.7 million, or 3.6% of assets. The company held $111.0 million in cash and equivalents against $220.3 million of debt, a net debt position of $109.3 million.
The current ratio (current assets divided by current liabilities) was 2.19, meaning short-term assets cover obligations due within a year. Debt-to-equity was 16.10.
Summary generated from market data by MetaCap's automated system. Methodology
Xeris Biopharma balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 111.04M | 71.62M | 67.45M | 121.97M | 67.27M | 37.60M |
| Short-Term Investments | — | 0 | 5.00M | 0 | 35.16M | 96.19M |
| Receivables | 51.05M | 40.41M | 39.20M | 30.83M | 17.46M | 6.88M |
| Inventory | 68.67M | 48.17M | 38.84M | 24.73M | 18.12M | 8.35M |
| Total Current Assets | 240.31M | 167.66M | 156.26M | 186.82M | 142.60M | 152.21M |
| Property, Plant & Equipment | 4.95M | 5.56M | 5.97M | 5.52M | 6.63M | 6.71M |
| Goodwill | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M | 0 |
| Intangible Assets | 88.08M | 98.92M | 109.76M | 120.61M | 131.45M | 0 |
| Total Assets | 383.53M | 323.06M | 322.60M | 344.52M | 304.36M | 159.15M |
| Accounts Payable | 3.08M | 2.29M | 11.56M | 4.61M | 8.92M | 3.12M |
| Short-Term Debt | 0 | 15.10M | 0 | — | — | — |
| Total Current Liabilities | 109.57M | 100.44M | 95.19M | 73.62M | 79.04M | 28.21M |
| Long-Term Debt | 220.34M | 217.01M | 190.93M | 187.07M | 88.07M | 87.02M |
| Total Liabilities | 369.84M | 352.68M | 329.38M | 299.33M | 209.13M | 125.39M |
| Shareholders' Equity | 13.69M | -29.61M | -6.78M | 45.19M | 95.23M | 33.76M |
| Retained Earnings | -671.31M | -671.86M | -617.02M | -554.77M | -460.11M | -337.38M |
| Total Debt | 220.34M | 232.11M | 190.93M | 187.07M | 88.07M | 87.02M |
| Net Cash (Debt) | -109.29M | -160.49M | -118.48M | -65.11M | 14.37M | 46.77M |
| Shares Outstanding | 166.22M | 149.43M | 138.13M | 136.27M | 124.87M | 59.61M |
This table shows 6 annual periods of Xeris Biopharma's balance sheet, from FY 2025 back to FY 2020, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow XERS's reporting calendar. What is a balance sheet?